PDCD1 and neoplasm: The IL-34KO tumors responded better to anti-PD-1 antibody therapy, as evidenced by reduced tumor sizes in comparison to the control IgG; however the favorable effects of PD-1 blocking were canceled out by IL-34, which is produced by tumor cells (60).